Comments
Loading...

Pfizer Analyst Ratings

PFENYSE
Logo brought to you by Benzinga Data
$24.20
0.271.13%
At close: -
$24.20
0.000.00%
After Hours: 5:47 PM EDT
The dividend Ex-Date is in 7 days
Q1 2025 Earnings were released on Tue Apr 29th, before the market open
The most recent conference call was at 10:00 AM, 3 days ago Click to view past webcast
Consensus Rating1
Neutral
Highest Price Target1
$50.00
Lowest Price Target1
$24.00
Consensus Price Target1
$33.32

Pfizer Analyst Ratings and Price Targets | NYSE:PFE | Benzinga

Pfizer Inc has a consensus price target of $33.32 based on the ratings of 24 analysts. The high is $50 issued by HSBC on July 14, 2023. The low is $24 issued by Cantor Fitzgerald on April 22, 2025. The 3 most-recent analyst ratings were released by UBS, Cantor Fitzgerald, and UBS on April 30, 2025, April 22, 2025, and April 8, 2025, respectively. With an average price target of $24.33 between UBS, Cantor Fitzgerald, and UBS, there's an implied 0.55% upside for Pfizer Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
2
Jan
1
1
Feb
2
Mar
4
Apr
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
2.6
Hold
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

UBS
Cantor Fitzgerald
Goldman Sachs
UBS
Citigroup

1calculated from analyst ratings

Analyst Ratings for Pfizer

Buy NowGet Alert
04/30/2025Buy Now3.31%UBS
Trung Huynh66%
$24 → $25MaintainsNeutralGet Alert
04/22/2025Buy Now-0.83%Cantor Fitzgerald
Carter Gould60%
→ $24Initiates → NeutralGet Alert
04/08/2025Buy Now-0.83%UBS
Trung Huynh66%
$28 → $24MaintainsNeutralGet Alert
04/08/2025Buy Now3.31%Goldman Sachs
Asad Haider 65%
$32 → $25DowngradeBuy → NeutralGet Alert
03/18/2025Buy NowGuggenheim
Vamil Divan76%
ReiteratesBuy → BuyGet Alert
03/12/2025Buy NowGuggenheim
Vamil Divan76%
ReiteratesBuy → BuyGet Alert
02/10/2025Buy Now36.36%Guggenheim
Vamil Divan76%
$33 → $33ReiteratesBuy → BuyGet Alert
02/05/2025Buy Now15.7%UBS
Colin Bristow42%
$29 → $28MaintainsNeutralGet Alert
01/28/2025Buy Now19.83%Citigroup
Andrew Baum72%
$30 → $29MaintainsNeutralGet Alert
01/08/2025Buy Now19.83%UBS
Colin Bristow42%
$31 → $29MaintainsNeutralGet Alert
12/18/2024Buy Now32.23%Truist Securities
Srikripa Devarakonda47%
$36 → $32MaintainsBuyGet Alert
12/11/2024Buy Now36.36%Guggenheim
Vamil Divan76%
$35 → $33MaintainsBuyGet Alert
12/10/2024Buy Now19.83%B of A Securities
Tim Anderson62%
→ $29Reinstates → NeutralGet Alert
11/15/2024Buy Now3.31%Wolfe Research
Alexandria Hammond64%
→ $25Initiates → UnderperformGet Alert
10/30/2024Buy Now28.1%Morgan Stanley
Terence Flynn67%
$30 → $31MaintainsEqual-WeightGet Alert
10/25/2024Buy Now85.95%Cantor Fitzgerald
Louise Chen56%
$45 → $45ReiteratesOverweight → OverweightGet Alert
10/23/2024Buy Now85.95%Cantor Fitzgerald
Louise Chen56%
$45 → $45ReiteratesOverweight → OverweightGet Alert
10/17/2024Buy Now32.23%Bernstein
Courtney Breen1%
→ $32Initiates → Market PerformGet Alert
10/11/2024Buy Now23.97%Morgan Stanley
Terence Flynn67%
$31 → $30MaintainsEqual-WeightGet Alert
10/03/2024Buy Now85.95%Cantor Fitzgerald
Louise Chen56%
$45 → $45ReiteratesOverweight → OverweightGet Alert
09/16/2024Buy Now85.95%Cantor Fitzgerald
Louise Chen56%
$45 → $45ReiteratesOverweight → OverweightGet Alert
09/09/2024Buy Now85.95%Cantor Fitzgerald
Louise Chen56%
$45 → $45ReiteratesOverweight → OverweightGet Alert
08/19/2024Buy Now85.95%Cantor Fitzgerald
Louise Chen56%
$45 → $45ReiteratesOverweight → OverweightGet Alert
08/08/2024Buy Now40.5%Daiwa Capital
Narumi Nakagiri23%
$28 → $34UpgradeNeutral → OutperformGet Alert
07/31/2024Buy Now28.1%Morgan Stanley
Terence Flynn67%
$29 → $31MaintainsEqual-WeightGet Alert
07/31/2024Buy Now32.23%Barclays
Carter Gould60%
$30 → $32MaintainsEqual-WeightGet Alert
07/31/2024Buy Now23.97%Wells Fargo
Mohit Bansal72%
$28 → $30MaintainsEqual-WeightGet Alert
07/31/2024Buy Now85.95%Cantor Fitzgerald
Louise Chen56%
$45 → $45ReiteratesOverweight → OverweightGet Alert
07/31/2024Buy Now28.1%UBS
Colin Bristow42%
$30 → $31MaintainsNeutralGet Alert
07/12/2024Buy Now23.97%UBS
Colin Bristow42%
$28 → $30MaintainsNeutralGet Alert
07/10/2024Buy Now23.97%Barclays
Carter Gould60%
$28 → $30MaintainsEqual-WeightGet Alert
07/10/2024Buy Now85.95%Cantor Fitzgerald
Louise Chen56%
$45 → $45ReiteratesOverweight → OverweightGet Alert
07/01/2024Buy Now85.95%Cantor Fitzgerald
Louise Chen56%
$45 → $45ReiteratesOverweight → OverweightGet Alert
06/26/2024Buy Now85.95%Cantor Fitzgerald
Louise Chen56%
$45 → $45ReiteratesOverweight → OverweightGet Alert
06/20/2024Buy Now85.95%Cantor Fitzgerald
Louise Chen56%
$45 → $45ReiteratesOverweight → OverweightGet Alert
06/17/2024Buy Now85.95%Cantor Fitzgerald
Louise Chen56%
$45 → $45ReiteratesOverweight → OverweightGet Alert
05/02/2024Buy Now19.83%Morgan Stanley
Terence Flynn67%
$28 → $29MaintainsEqual-WeightGet Alert
05/02/2024Buy Now48.76%BMO Capital
Evan David Seigerman51%
$33 → $36ReiteratesOutperform → OutperformGet Alert
04/18/2024Buy Now85.95%Cantor Fitzgerald
Louise Chen56%
$45 → $45ReiteratesOverweight → OverweightGet Alert
04/15/2024Buy Now85.95%Cantor Fitzgerald
Louise Chen56%
$45 → $45ReiteratesOverweight → OverweightGet Alert
04/05/2024Buy Now85.95%Cantor Fitzgerald
Louise Chen56%
$45 → $45ReiteratesOverweight → OverweightGet Alert
04/01/2024Buy Now85.95%Cantor Fitzgerald
Louise Chen56%
$45 → $45ReiteratesOverweight → OverweightGet Alert
03/31/2024Buy Now19.83%Morgan Stanley
Terence Flynn67%
$28 → $29MaintainsEqual-WeightGet Alert
03/22/2024Buy NowArgus Research
David Toung71%
DowngradeBuy → HoldGet Alert
03/04/2024Buy Now85.95%Cantor Fitzgerald
Louise Chen56%
$45 → $45ReiteratesOverweight → OverweightGet Alert
03/01/2024Buy Now85.95%Cantor Fitzgerald
Louise Chen56%
$45 → $45ReiteratesOverweight → OverweightGet Alert
02/23/2024Buy Now48.76%Guggenheim
Vamil Divan76%
→ $36Initiates → BuyGet Alert
01/31/2024Buy Now15.7%UBS
Colin Bristow42%
$29 → $28MaintainsNeutralGet Alert
01/31/2024Buy Now85.95%Cantor Fitzgerald
Louise Chen56%
$45 → $45ReiteratesOverweight → OverweightGet Alert
01/17/2024Buy Now19.83%UBS
Colin Bristow42%
$27 → $29MaintainsNeutralGet Alert
01/09/2024Buy Now85.95%Cantor Fitzgerald
Louise Chen56%
$45 → $45ReiteratesOverweight → OverweightGet Alert
01/04/2024Buy Now32.23%TD Cowen
Steve Scala10%
→ $32DowngradeOutperform → Market PerformGet Alert
12/14/2023Buy Now15.7%Wells Fargo
Mohit Bansal72%
$35 → $28MaintainsEqual-WeightGet Alert
12/14/2023Buy Now85.95%Cantor Fitzgerald
Louise Chen56%
$75 → $45MaintainsOverweightGet Alert
12/14/2023Buy Now48.76%Truist Securities
Robyn Karnauskas55%
$42 → $36MaintainsBuyGet Alert
12/14/2023Buy Now11.57%UBS
Colin Bristow42%
$34 → $27MaintainsNeutralGet Alert
12/14/2023Buy Now15.7%Barclays
Carter Gould60%
$34 → $28MaintainsEqual-WeightGet Alert
12/04/2023Buy Now73.55%Truist Securities
Robyn Karnauskas55%
→ $42ReiteratesBuy → BuyGet Alert
11/20/2023Buy Now209.92%Cantor Fitzgerald
Louise Chen56%
→ $75ReiteratesOverweight → OverweightGet Alert
11/01/2023Buy Now40.5%Barclays
Carter Gould60%
$35 → $34MaintainsEqual-WeightGet Alert
11/01/2023Buy Now52.89%Morgan Stanley
Terence Flynn67%
$39 → $37MaintainsEqual-WeightGet Alert
10/20/2023Buy Now40.5%UBS
Colin Bristow42%
$36 → $34AssumesNeutral → NeutralGet Alert
10/17/2023Buy Now73.55%Truist Securities
Robyn Karnauskas55%
$62 → $42MaintainsBuyGet Alert
10/17/2023Buy Now61.16%Morgan Stanley
Terence Flynn67%
$40 → $39MaintainsEqual-WeightGet Alert
10/17/2023Buy Now44.63%Wells Fargo
Mohit Bansal72%
$39 → $35MaintainsEqual-WeightGet Alert
10/16/2023Buy Now36.36%BMO Capital
Evan David Seigerman51%
$44 → $33MaintainsOutperformGet Alert
10/16/2023Buy Now44.63%Citigroup
Andrew Baum72%
$42 → $35MaintainsNeutralGet Alert
10/16/2023Buy Now40.5%JP Morgan
Chris Schott60%
$36 → $34MaintainsNeutralGet Alert
10/16/2023Buy Now44.63%Wells Fargo
Mohit Bansal72%
$39 → $35MaintainsEqual-WeightGet Alert
10/16/2023Buy Now61.16%Jefferies
Akash Tewari45%
$38 → $39UpgradeHold → BuyGet Alert
10/06/2023Buy Now48.76%JP Morgan
Chris Schott60%
$39 → $36MaintainsNeutralGet Alert
10/02/2023Buy Now209.92%Cantor Fitzgerald
Louise Chen56%
→ $75ReiteratesOverweight → OverweightGet Alert
09/18/2023Buy Now209.92%Cantor Fitzgerald
Louise Chen56%
→ $75ReiteratesOverweight → OverweightGet Alert
09/13/2023Buy Now156.2%Truist Securities
Robyn Karnauskas55%
→ $62ReiteratesBuy → BuyGet Alert
09/05/2023Buy Now209.92%Cantor Fitzgerald
Louise Chen56%
→ $75ReiteratesOverweight → OverweightGet Alert
08/30/2023Buy Now209.92%Cantor Fitzgerald
Louise Chen56%
→ $75ReiteratesOverweight → OverweightGet Alert
08/22/2023Buy Now209.92%Cantor Fitzgerald
Louise Chen56%
→ $75ReiteratesOverweight → OverweightGet Alert
08/02/2023Buy Now156.2%Truist Securities
Robyn Karnauskas55%
$64 → $62MaintainsBuyGet Alert
08/02/2023Buy Now65.29%Morgan Stanley
Terence Flynn67%
$42 → $40MaintainsEqual-WeightGet Alert
08/02/2023Buy Now81.82%BMO Capital
Evan David Seigerman51%
$45 → $44MaintainsOutperformGet Alert
07/21/2023Buy Now73.55%Morgan Stanley
Terence Flynn67%
$43 → $42MaintainsEqual-WeightGet Alert
07/14/2023Buy Now106.61%HSBC
Rajesh Kumar60%
→ $50Initiates → BuyGet Alert
07/11/2023Buy Now77.69%Morgan Stanley
Terence Flynn67%
$43 → $43ReiteratesEqual-Weight → Equal-WeightGet Alert
07/11/2023Buy Now57.02%Barclays
Carter Gould60%
$40 → $38MaintainsEqual-WeightGet Alert
06/29/2023Buy Now65.29%Credit Suisse
Trung Huynh66%
$47 → $40DowngradeOutperform → NeutralGet Alert
06/23/2023Buy Now209.92%Cantor Fitzgerald
Louise Chen56%
$75 → $75ReiteratesOverweight → OverweightGet Alert
06/22/2023Buy Now209.92%Cantor Fitzgerald
Louise Chen56%
→ $75ReiteratesOverweight → OverweightGet Alert
05/17/2023Buy Now209.92%Cantor Fitzgerald
Louise Chen56%
→ $75ReiteratesOverweight → OverweightGet Alert
05/11/2023Buy Now57.02%Daiwa Capital
Narumi Nakagiri23%
$51 → $38DowngradeOutperform → NeutralGet Alert
05/03/2023Buy Now94.21%Credit Suisse
Trung Huynh66%
$50 → $47MaintainsOutperformGet Alert
05/03/2023Buy Now65.29%Barclays
Carter Gould60%
$43 → $40MaintainsEqual-WeightGet Alert
04/21/2023Buy Now85.95%B of A Securities
Geoff Meacham69%
$50 → $45MaintainsNeutralGet Alert
04/12/2023Buy Now77.69%Barclays
Carter Gould60%
$44 → $43MaintainsEqual-WeightGet Alert
04/10/2023Buy Now81.82%Morgan Stanley
Terence Flynn67%
$45 → $44MaintainsEqual-WeightGet Alert
03/17/2023Buy Now81.82%Wells Fargo
Mohit Bansal72%
$50 → $44MaintainsEqual-WeightGet Alert
03/06/2023Buy Now77.69%Jefferies
Akash Tewari45%
→ $43Initiates → HoldGet Alert
02/07/2023Buy Now110.74%Daiwa Capital
Narumi Nakagiri23%
→ $51UpgradeNeutral → OutperformGet Alert
02/01/2023Buy Now85.95%Morgan Stanley
Terence Flynn67%
$53 → $45MaintainsEqual-WeightGet Alert
02/01/2023Buy Now209.92%Cantor Fitzgerald
Louise Chen56%
→ $75Reiterates → OverweightGet Alert
02/01/2023Buy Now106.61%Credit Suisse
Trung Huynh66%
$54 → $50MaintainsOutperformGet Alert

FAQ

Q

What is the target price for Pfizer (PFE) stock?

A

The latest price target for Pfizer (NYSE:PFE) was reported by UBS on April 30, 2025. The analyst firm set a price target for $25.00 expecting PFE to rise to within 12 months (a possible 3.31% upside). 36 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Pfizer (PFE)?

A

The latest analyst rating for Pfizer (NYSE:PFE) was provided by UBS, and Pfizer maintained their neutral rating.

Q

When was the last upgrade for Pfizer (PFE)?

A

The last upgrade for Pfizer Inc happened on August 8, 2024 when Daiwa Capital raised their price target to $34. Daiwa Capital previously had a neutral for Pfizer Inc.

Q

When was the last downgrade for Pfizer (PFE)?

A

The last downgrade for Pfizer Inc happened on April 8, 2025 when Goldman Sachs changed their price target from $32 to $25 for Pfizer Inc.

Q

When is the next analyst rating going to be posted or updated for Pfizer (PFE)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Pfizer, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Pfizer was filed on April 30, 2025 so you should expect the next rating to be made available sometime around April 30, 2026.

Q

Is the Analyst Rating Pfizer (PFE) correct?

A

While ratings are subjective and will change, the latest Pfizer (PFE) rating was a maintained with a price target of $24.00 to $25.00. The current price Pfizer (PFE) is trading at is $24.20, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch